You can buy or sell ZYNE and other stocks, options, and ETFs commission-free!
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA. The listed name for ZYNE is Zynerba Pharmaceuticals, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 9, Pre-Market